Ian Mortimer, PRESIDENT & CEO at Xenon Pharmaceuticals Inc. (XENE), sold 108,851 shares at $40.46 ($4.4M) on 2025-01-27, disclosed to the SEC on 2025-01-27.
Scheduled sale ($4.4M) by PRESIDENT & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.08 | 16,217 | $650K | 14.8% |
| 2 | $40.08 | 16,217 | $650K | 14.8% |
| 3 | $40.20 | 22,468 | $903K | 20.6% |
| 4 | $40.20 | 22,468 | $903K | 20.6% |
| 5 | $40.46 | 15,166 | $614K | 14.0% |
| 6 | $40.46 | 15,166 |
| $614K |
| 14.0% |
| 7 | $41.07 | 1,149 | $47K | 1.1% |
| Total | $40.25 avg | 108,851 | $4.4M | 100% |
| Filing → |
| XENE | SELL | 2026-03-11 | $17.6M | — | Filing → |
| XENE | SELL | 2026-01-02 | $1.8M | — | Filing → |
| XENE | SELL | 2025-12-09 | $2.3M | — | Filing → |